IRulya Therapeutics (QNCX) Stock News
$QNCX · NASDAQ · 2 stories in 30 daysBORSA has published 2 stories on IRulya Therapeutics (QNCX) in the past 30 days, 1 of them high impact. BORSA’s news read on QNCX is bullish at 72/100, unchanged over 24 hours, based on 1 company event over the past 30 days. QNCX last closed at $31.73 on Oct 9, up 8.66% over five sessions and up 9.56% over the past month.
The wire on $QNCX
newest first · updated · direct subject stories onlyQuince Therapeutics Relaunches as IRulya Therapeutics, Focuses on LAM-001 for Pulmonary Disease
Quince Therapeutics (QNCX) renamed IRulya Therapeutics, new ticker IRLA effective Oct 12. New CEO, CFO, COO. Cash $116M funds through 2028. Phase 2 data readouts for LAM-001 in BOS (Q1 2027), PH-ILD (Q1 2028), SAPH (Q4 2028).
neutral 50 · impact 70